tldrdailynews.com logo
Tag

Pancreatic Cancer

All articles tagged with #pancreatic cancer

Routine Heart Scan Leads to Early Pancreatic Cancer Diagnosis and Successful Surgery for Cape Cod Bookstore Owner
health3 days ago

Routine Heart Scan Leads to Early Pancreatic Cancer Diagnosis and Successful Surgery for Cape Cod Bookstore Owner

Vicky Titcomb, a 72-year-old Cape Cod bookstore owner, was diagnosed with pancreatic cancer after an abnormality was discovered during a routine heart scan in March 2025. Despite the disease's low overall survival rate, Titcomb underwent chemotherapy, radiation, and a robotic Whipple procedure at Mass General Brigham. By March 2026, she reported no evidence of cancer and is now advocating for early detection and treatment advancements.

via CBS News|
#cancer-survival#early-detection#health
Early Detection and New RAS Inhibitors Aim to Triple Pancreatic Cancer Survival
health11 days ago

Early Detection and New RAS Inhibitors Aim to Triple Pancreatic Cancer Survival

Researchers are pursuing a strategy of 'cancer interception' to treat pre-cancerous pancreatic tissue before it becomes malignant, aiming to boost five-year survival from 13.7% to 50%. This approach leverages the recent FDA approval of daraxonrasib, a drug that nearly doubled median survival in metastatic cases. While current trials focus on advanced disease, new studies are testing the drug for early-stage prevention and screening.

via nature.com|
#cancer-interception#daraxonrasib#early-detection
FDA Approves First RAS Inhibitor, Doubling Survival for Pancreatic Cancer Patients
health13 days ago

FDA Approves First RAS Inhibitor, Doubling Survival for Pancreatic Cancer Patients

The FDA has approved daraxonrasib (Rasonque), the first drug in its class to target RAS mutations, a breakthrough for pancreatic cancer. In a trial of 500 patients, the drug doubled median survival to 13.2 months compared to 6.7 months for chemotherapy. Developed by Revolution Medicines, the drug addresses a target previously deemed untargetable, offering new hope for a disease with a 13% five-year survival rate.

via Gizmodo|
#daraxonrasib#fda-approval#health
health17 days ago

mRNA Cocktail Erases Pancreatic Tumors in Half of Mice

A new mRNA-based immunotherapy has shown unprecedented success in animal models of pancreatic cancer. Researchers at UMass Chan Medical School developed a single injection combining five cytokine mRNAs and three tumor-associated antigens. In mice with pancreatic ductal adenocarcinoma, approximately 50% experienced complete tumor regression that lasted up to one year after treatment stopped. The therapy works by weakening the fibrotic barrier around tumors and training the immune system to recognize cancer cells, potentially creating long-term immune memory. While mouse results do not guarantee human success, the team is developing an IND-ready product for clinical trials.

via SciTechDaily|
#health#immunotherapy#mrna-therapy
New Blood Test Detects Early Pancreatic Cancer with 87% Accuracy
health26 days ago

New Blood Test Detects Early Pancreatic Cancer with 87% Accuracy

A new blood test called PANXEON has shown promising results in detecting early-stage pancreatic cancer, with a sensitivity of 86.8% for stages I-II and a low false-positive rate in low-risk groups. The test uses a combination of microRNA signatures and carbohydrate antigen 19-9 levels to identify the disease before symptoms appear, potentially improving survival rates for a cancer that is currently diagnosed at late stages in most cases.

via Nature|
#biomarkers#early-detection#health
FDA clears pancreatic cancer breakthrough, but insurance lags behind
health1 month ago

FDA clears pancreatic cancer breakthrough, but insurance lags behind

FDA approved Revolution Medicines’ pancreatic cancer drug Rasonque last month, a potential median-survival boost, but the closure of expanded-access programs and the slow pace of insurer coverage created a gap for patients like Juan Solano. The drug carries a near-$40,000 monthly price, and while patient-access programs and later insurer actions provided some relief, many families face a confusing, time-consuming path to obtain treatment after FDA clearance, underscoring a broader need for policy and payer systems to expedite coverage after approvals.

via STAT|
#cancer-drug#fda-approval#health
Pancreatic cancer drug shows early promise against lung cancer
health1 month ago

Pancreatic cancer drug shows early promise against lung cancer

A small trial of daraxonrasib (Rasonque) in non-small-cell lung cancer with RAS mutations showed tumor shrinkage in more than 30% of participants, signaling potential beyond pancreatic cancer. A larger randomized trial is under way to confirm efficacy and durability, with regulatory decisions pending. The drug, which had already received FDA approval for pancreatic cancer after earlier successes, works as a molecular glue that exposes RAS to inhibition via cyclophilin A, a mechanism that could extend to other hard-to-treat tumors, though resistance can emerge.

via Nature|
#clinical-trial#daraxonrasib#health
Rasonque poised to reshape pancreatic cancer therapy with blockbuster potential
business1 month ago

Rasonque poised to reshape pancreatic cancer therapy with blockbuster potential

Revolution Medicines’ pancreatic cancer drug Rasonque will list at $39,800 for a 30-day supply, a price analysts say could help it become a blockbuster; Evercore ISI raised pancreatic cancer sales forecasts to about $2.4 billion next year and up to $15.1 billion by 2034, with potential expansion to other cancers. The FDA approved the drug for patients who’ve had one systemic therapy or aren’t candidates for multiagent therapy, and a Phase 3 front-line trial is underway, signaling strong launch momentum despite the steep price.

via BioPharma Dive|
#business#drug-pricing#fda-approval
Pancreatic cancer drug arrives with a $39,800 monthly price, but costs depend on coverage and aid
health1 month ago

Pancreatic cancer drug arrives with a $39,800 monthly price, but costs depend on coverage and aid

FDA approves Revolution Medicines’ oral daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma after phase 3 results showing a 60% reduction in death risk and median survival of 13.2 months versus 6.7 with chemotherapy. The wholesale list price is about $39,800 for a 30‑day supply (roughly $477,000/year), but patients’ out‑of‑pocket costs vary with insurance; Medicare Part D and discounts can reduce costs by about 20–30%, and aid programs (e.g., Path) may offer low or zero copays for eligible patients. Side effects include rash, diarrhea, mucositis, nausea, fatigue, and edema. The drug is not a cure but offers a life‑extending option for a historically hard‑to‑treat cancer; about 67,000 pancreatic cancer diagnoses are expected in 2026.

via Yahoo Finance|
#drug-pricing#fda-approval#financial-assistance
Rasonque Debuts in Pancreatic Cancer as Investors Eye a Historic Launch
healthcare1 month ago

Rasonque Debuts in Pancreatic Cancer as Investors Eye a Historic Launch

Revolution Medicines wins FDA approval for Rasonque (daraxonrasib) in metastatic pancreatic cancer, triggering optimism of a historic oncology launch and potential multi‑billion sales, but raising questions about first‑line use, payer coverage, and how quickly patients move from expanded‑access to commercial treatment amid a $39,800 monthly price and a broad label whose criteria for multiagent therapy remain unclear.

via Fierce Pharma|
#drug-pricing#expanded-access-program#healthcare
KRAS-targeting pancreatic cancer pill approved, signaling a broader oncology breakthrough
health1 month ago

KRAS-targeting pancreatic cancer pill approved, signaling a broader oncology breakthrough

The FDA approved Revolution Medicines’ Rasonque, a daily KRAS-targeting pill for adults with metastatic pancreatic adenocarcinoma after one prior therapy or when chemotherapy isn’t feasible. In trials, median overall survival more than doubled (13.2 months vs 6.7) and death risk was reduced by about 60%, with no KRAS mutation test required. Priced at $39,800 per 30 days and backed by patient-support and expanded-access programs, the approval is viewed as a major advance and a potential platform for RAS-driven cancers, with off-label use anticipated and ongoing development of related therapies.

via Fortune|
#fda-approval#health#oncology
New KRAS-Targeting Drug Extends Pancreatic Cancer Survival, FDA Approves Breakthrough Therapy
health1 month ago

New KRAS-Targeting Drug Extends Pancreatic Cancer Survival, FDA Approves Breakthrough Therapy

The FDA has approved daraxonrasib (Rasonque) from Revolution Medicines to treat pancreatic cancer, after a phase 3 trial where patients on the daily pill had a median survival of 13.2 months versus 6.6 months on chemotherapy. The drug targets the mutated KRAS gene, present in more than 90% of pancreatic tumors, potentially altering a historically hard-to-treat cancer. About 67,000 Americans are diagnosed each year, with more than half dying within three months of diagnosis. The FDA granted Breakthrough Therapy designation in 2025.

via BBC|
#breakthrough-therapy#fda-approval#health